Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
-
Published:2024-08
Issue:8
Volume:30
Page:772.e1-772.e11
-
ISSN:2666-6367
-
Container-title:Transplantation and Cellular Therapy
-
language:en
-
Short-container-title:Transplantation and Cellular Therapy
Author:
Pasvolsky Oren, Marcoux Curtis, Dai Jianliang, Milton Denái R., Tanner Mark R., Syed NaureenORCID, Bashir QaiserORCID, Srour Samer, Saini Neeraj, Lin PaulORCID, Ramdial Jeremy, Nieto YagoORCID, Tang Guilin, Aljawai YosraORCID, Lee Hans C., Gaballa Mahmoud RORCID, Patel Krina K., Kebriaei Partow, Thomas Sheeba K., Orlowski Robert Z., Shpall Elizabeth J., Champlin Richard E.ORCID, Qazilbash Muzaffar H.
Reference36 articles.
1. Epidemiology, staging, and management of multiple myeloma;Padala;Med Sci (Basel),2021 2. Updated diagnostic criteria and staging system for multiple myeloma;Rajkumar;Am Soc Clin Oncol Educ Book,2016 3. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial;Harousseau;J Clin Oncol,2010 4. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma;Lokhorst;Blood,2010 5. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results;Morgan;Haematologica,2012
|
|